Literature DB >> 33659330

Genomic Edition of Ashbya gossypii Using One-vector CRISPR/Cas9.

Gloria Muñoz-Fernández1, Alberto Jiménez1, José Luis Revuelta1.   

Abstract

The CRISPR/Cas9 system is a novel genetic tool which allows the precise manipulation of virtually any genomic sequence. In this protocol, we use a specific CRISPR/Cas9 system for the manipulation of Ashbya gossypii. The filamentous fungus A. gossypii is currently used for the industrial production of riboflavin (vitamina B2). In addition, A. gossypii produces other high-value compounds such as folic acid, nucleosides and biolipids. A large molecular toolbox is available for the genomic manipulation of this fungus including gene targeting methods, rapid assembly of heterologous expression modules and, recently, a one-vector CRISPR/Cas9 editing system adapted for A. gossypii that allows marker-free engineering strategies to be implemented. The CRISPR/Cas9 system comprises an RNA guided DNA endonuclease (Cas9) and a guide RNA (gRNA), which is complementary to the genomic target region. The Cas9 nuclease requires a 5'-NGG-3' trinucleotide, called protospacer adjacent motif (PAM), to generate a double-strand break (DSB) in the genomic target, which can be repaired with a synthetic mutagenic donor DNA (dDNA) by homologous recombination (HR), thus introducing a specific designed mutation. The CRISPR/Cas9 system adapted for A. gossypii largely facilitates the genomic edition of this industrial fungus.
Copyright © 2020 The Authors; exclusive licensee Bio-protocol LLC.

Entities:  

Keywords:  Ashbya gossypii; Biotechnology; CRISPR/Cas9; Gene editing; Genome engineering; One-vector

Year:  2020        PMID: 33659330      PMCID: PMC7842619          DOI: 10.21769/BioProtoc.3660

Source DB:  PubMed          Journal:  Bio Protoc        ISSN: 2331-8325


  9 in total

Review 1.  CRISPR/Cas, the immune system of bacteria and archaea.

Authors:  Philippe Horvath; Rodolphe Barrangou
Journal:  Science       Date:  2010-01-08       Impact factor: 47.728

2.  Metabolic engineering of the purine pathway for riboflavin production in Ashbya gossypii.

Authors:  Alberto Jiménez; María A Santos; Markus Pompejus; José L Revuelta
Journal:  Appl Environ Microbiol       Date:  2005-10       Impact factor: 4.792

3.  Multiplex metabolic pathway engineering using CRISPR/Cas9 in Saccharomyces cerevisiae.

Authors:  Tadas Jakočiūnas; Ida Bonde; Markus Herrgård; Scott J Harrison; Mette Kristensen; Lasse E Pedersen; Michael K Jensen; Jay D Keasling
Journal:  Metab Eng       Date:  2015-01-28       Impact factor: 9.783

4.  Genome engineering using the CRISPR-Cas9 system.

Authors:  F Ann Ran; Patrick D Hsu; Jason Wright; Vineeta Agarwala; David A Scott; Feng Zhang
Journal:  Nat Protoc       Date:  2013-10-24       Impact factor: 13.491

5.  A programmable dual-RNA-guided DNA endonuclease in adaptive bacterial immunity.

Authors:  Martin Jinek; Krzysztof Chylinski; Ines Fonfara; Michael Hauer; Jennifer A Doudna; Emmanuelle Charpentier
Journal:  Science       Date:  2012-06-28       Impact factor: 47.728

6.  Homology-integrated CRISPR-Cas (HI-CRISPR) system for one-step multigene disruption in Saccharomyces cerevisiae.

Authors:  Zehua Bao; Han Xiao; Jing Liang; Lu Zhang; Xiong Xiong; Ning Sun; Tong Si; Huimin Zhao
Journal:  ACS Synth Biol       Date:  2014-09-19       Impact factor: 5.110

7.  Genome engineering in Saccharomyces cerevisiae using CRISPR-Cas systems.

Authors:  James E DiCarlo; Julie E Norville; Prashant Mali; Xavier Rios; John Aach; George M Church
Journal:  Nucleic Acids Res       Date:  2013-03-04       Impact factor: 16.971

8.  High-throughput profiling of off-target DNA cleavage reveals RNA-programmed Cas9 nuclease specificity.

Authors:  Vikram Pattanayak; Steven Lin; John P Guilinger; Enbo Ma; Jennifer A Doudna; David R Liu
Journal:  Nat Biotechnol       Date:  2013-08-11       Impact factor: 54.908

9.  One-vector CRISPR/Cas9 genome engineering of the industrial fungus Ashbya gossypii.

Authors:  Alberto Jiménez; Gloria Muñoz-Fernández; Rodrigo Ledesma-Amaro; Rubén M Buey; José L Revuelta
Journal:  Microb Biotechnol       Date:  2019-05-05       Impact factor: 5.813

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.